Evotec SE announced the launch of J.TRAIN, a turnkey solution enabling biopharmaceutical companies to deploy its proprietary continuous manufacturing technology directly within their own facilities. The new offering, unveiled on June 30, 2026, combines prefabricated modular cleanrooms and industry-standard equipment with cGMP-compliant process automation to accelerate capacity expansion. J.TRAIN is designed to offer significantly faster and more cost-effective deployment compared to traditional manufacturing expansion methods.

The solution represents a strategic shift for Just – Evotec Biologics, a wholly-owned subsidiary of Evotec SE, toward a technology-focused and capital-lighter business model. Linda Zuckerman, PhD, EVP Global Head of Just – Evotec Biologics, highlighted that the model was validated by a December 2025 transaction with Sandoz. This transaction included the provision of a manufacturing facility alongside a license to the proprietary manufacturing technology, demonstrating its feasibility and scalability.

J.TRAIN aims to deliver a step change in productivity and efficiency compared to conventional fed-batch approaches. The system can enable the production of more than 500 kilograms of drug substance from less than 10,000 square feet of cleanroom space. This configuration achieves productivity levels more than ten times traditional methods, which is expected to translate into substantially lower operating costs per unit mass.

The integrated design allows for rapid transitions between products, minimizing downtime and supporting multi-product manufacturing environments. Production scale can be flexibly adjusted through the duration of manufacturing runs rather than relying on the size of the facility. Proprietary automation scripts for continuous process control, along with digital validation and documentation protocols, are included to streamline implementation and ensure regulatory readiness.

With deployment timelines of approximately 18 months, J.TRAIN offers a faster pathway to capacity expansion than traditional biologics manufacturing facilities. The solution was initially unveiled in April 2026 at the INTERPHEX conference in New York City.

Key Features of J.TRAIN